249 results about "Steatosis" patented technology

The present invention relates to the use of a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone for treating NAFLD / NASH and advanced liver fibrosis by decreased serum cholesterol and triglycerides as well as reducing the content of hepatic fat accumulation, both in the form of macrosteatosis and microsteatosis. Additionally, its use as an agonist for PPARgamma (peroxisome proliferation receptor activated gamma), PPARalpha (peroxisome proliferation receptor activated alpha), LXR and CPT1, key molecules in the metabolism of fatty degradation and inflammation of the liver. In addition, another use is the induction of decreased expression of NFKB master gene, transcriptional inducer of hepatic inflammatory process factor. All of these events results in the reversal of NAFLD / NASH and advanced liver fibrosis.

Systems and methods for capturing and processing image data captured by an optical microscope, such as an Open Top Light Sheet (OTLS) microscope are disclosed. Image data can be processed by techniques including flat fielding, image depth correction, and edge correction, and pixel classification and image segmentation techniques can be applied to more accurately identify lipid droplets and fibrous structures for assessment of, for example, steatosis and fibrosis in human liver biopsy tissue samples. Systems and methods are also related to capturing low resolution images of a sample, identifying regions of interest, and then capturing high resolution image of the regions of interest to reduce memory used for storage, increase computation speed, and reduce computational power.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The present invention discloses an image processing-based ultrasonic measurement method for hepatic steatosis. The method comprises preprocessing a set of RF signals from the abdominal region, including the liver, acquired by ultrasound imaging and converting the signals into a grayscale image; processing the grayscale image to obtain a first segmentation template for the liver region; removing interference signal regions from the first segmentation template to obtain a second segmentation template for the liver region; labeling the grayscale image with the second segmentation template to obtain a region of interest; and calculating an attenuation coefficient within the region of interest to characterize the degree of hepatic steatosis. This method allows the attenuation coefficient to be calculated only for sampling points within the liver and non-lesion areas, achieving more accurate hepatic steatosis measurement.

The invention belongs to the technical field of biological medicines, and particularly relates to application of beta-hydroxybutyrate in preparation of a medicine for preventing or treating hepatocellular carcinoma. The invention provides an application of beta-hydroxybutyrate in preparation of a medicine for preventing and / or treating hepatocellular carcinoma. The beta-hydroxybutyrate comprises a beta-hydroxybutyrate or a combination of a plurality of beta-hydroxybutyrates. A series of experimental data show that beta-hydroxybutyrate not only can effectively improve fatty degeneration and inflammatory response of hepatocytes, but also can remarkably reduce the risk of occurrence of metabolic dysfunction related hepatocellular carcinoma (HCC), and can inhibit malignant biological characteristics of HCC. The invention provides a powerful scientific basis for the development of novel HCC prevention and treatment medicines, and has a wide clinical application prospect.

Provided are a GLP-1GIP analog, an FGF21 protein, a trifunctional protein, and use thereof. The trifunctional protein comprises the GLP-1 / GIP analog and the FGF21 protein. Further provided is use of the GLP-1 / GIP analog, the FGF21 protein, and the trifunctional protein in the preparation of a drug for preventing and / or treating diseases related to GLP-1, GIP, and / or FGF21. The provided GLP-1 / GIP analog, FGF21 protein, and trifunctional protein can synergistically regulate blood glucose and lipid levels in vivo, meet multiple needs in patients with type 2 diabetes, including lowering blood glucose, alleviating hepatic steatosis, promoting weight loss, ameliorating circulating lipid metabolism disorder, etc., and have better biological safety and tolerability and longer in vivo half-lives.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

The present application relates to the field of medicine, and specifically to a GLP-1 analog fusion protein and its application. The GLP-1 analog fusion protein is obtained by fusing GLP-1 to the N-terminus of the IgG4 heavy chain constant region and the light chain constant region. The results of the study showed that the GLP-1 analog fusion protein of the present application has a significant effect on reducing the weight of mice. The volume and weight of the mouse liver decreased, and the NAS score and hepatic steatosis were significantly improved. Therefore, the present invention can be applied to drugs or products for weight loss or the treatment of fatty liver.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

This invention discloses a low-astringency prickly pear lactic acid bacteria fermented beverage and its application in lowering blood lipids and antioxidation, relating to the fields of microbial application and food fermentation technology. The fermented beverage of this invention uses prickly pear juice as raw material and is prepared by fermentation with *Lactobacillus plantarum* R-21. It can significantly reduce the tannin content of prickly pear juice, improve taste, and increase the polysaccharide content and antioxidant properties of the beverage. In vivo experiments show that it can reduce the levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in mouse liver and serum, inhibit fat accumulation and fatty degeneration in liver cells, and enhance the activity of antioxidant enzymes in the liver, demonstrating important application value in lowering blood lipids and antioxidation.

The invention discloses a preparation method of an edible flower phenol amide compound and application of the edible flower phenol amide compound in prevention and treatment of non-alcoholic fatty liver disease, and particularly relates to the field of development of new application of food raw materials. The edible flower phenol amide compound N1, N5, N10-coumaroyl spermidine (TCS) can be green extracted by using a natural deep-eutectic solvent (NADES), and can inhibit free fatty acid-induced liver cell lipid accumulation and improve fatty acid-caused liver cell fatty degeneration; oxidative stress and inflammation induced by free fatty acid are inhibited, and expression of senescence-related markers is inhibited, so that development of NAFLD is effectively inhibited.

Provided are a method for assisting in the detection of non-alcoholic steatohepatitis (NASH) with extremely low invasiveness compared to liver biopsy, without relying on the skill of a technician, by a simple operation; and a method for assisting in the determination of the degree of progression of a condition associated with NASH. Provided is a method for assisting in the detection of non-alcoholic steatohepatitis, the method comprising: measuring the presence of LDL-TG and / or ApoE-rich HDL-C contained in a blood sample isolated from an organism. Also provided is a method for assisting in the determination of the degree of progression of a condition associated with non-alcoholic steatohepatitis, the condition being at least one selected from the group consisting of steatosis, inflammation, ballooning degeneration, and fibrosis, the method comprising: measuring the presence of LDL-TG and / or ApoE-rich HDL-C contained in a blood sample isolated from an organism.

Provided are a method of assisting the detection of nonalcoholic steatohepatitis (NASH) and a method that is able to assist in determining the degree of progression of any condition associated with NASH, which are far less invasive than liver biopsy and include simple operations and are independent of the skills of technicians.The present invention provides a method of assisting the detection of nonalcoholic steatohepatitis, including measuring the abundance of LDL-TG and / or ApoE-rich HDL-C contained in a test blood sample isolated from a living body. Also, the present invention provides a method of assisting in determining the degree of progression of at least one medical condition associated with nonalcoholic steatohepatitis, which medical condition(s) is(are) selected from the group consisting of fatty degeneration (steatosis), inflammation, ballooning degeneration, and fibrosis, including measuring the abundance of LDL-TG and / or ApoE-rich HDL-C contained in a test blood sample isolated from a living body.

Despite the high prevalence and serious clinical implications of metabolic associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), MASH is usually overlooked in clinical practice, due to the lack of accurate biomarkers. The inventors evaluated the ability of plasma large extracellular vesicles (lEVs) to serve as noninvasive biomarkers for the diagnosis of MASH, in particular in T2D patients. Proteomic analysis identified Transferrinreceptor on lEVs (TFRC-lEVs) as associated with MASH. The inventors thus measured TFRC- lEVs on plasma samples from patients included in the derivation cohort. The proportion of patients with TFRC-lEVs concentration > 61 ng / mL was significantly higher in patients with MASH than in those with steatosis. TFRC-lEVs > 61 ng / mL remained associated with MASH after adjustment on either usual laboratory variables, or on the NASH-Test or on the Fibroscan FAST-score. When combining TFRC-lEVs with available methods the population suspected of having MASH was 32% and 29%, versus 22% and 16% for NASH-test or FAST score alone, without decreasing specificity. In conclusion, TFRC-lEVs, a marker of hepatocyte ballooning, is a promising biomarker for MASH. It could be used for patients' screening to enlarge recruitment of patients with MASH in clinical trials.

According to the application of the spleen-tonifying eight-treasure cake in the fat generation inhibiting and weight losing product, the spleen-tonifying eight-treasure cake product can remarkably reduce liver fatty degeneration, inhibit fat generation and improve liver functions by adjusting lipid metabolism, and the spleen-tonifying eight-treasure cake can remarkably reduce the weight, the weight gain, the liver index and the fat index of obese rats, so that the weight losing effect of the fat rats is improved, and the weight losing effect of the fat rats is improved. The weight and the body fat content of fat rats induced by high-fat diet are obviously reduced, so that the effects of inhibiting adipogenesis and losing weight are achieved.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

The invention discloses a traditional Chinese medicine composition and application thereof in medicine for improving non-alcoholic fatty liver, and the traditional Chinese medicine composition comprises pulvis fellis suis, pericarpium citri reticulatae, hawthorn and clostridium butyricum. On one hand, potential targets and pathways of drug diseases are determined in network pharmacological analysis, and on the other hand, in an in-vivo experiment, the drug provided by the invention improves obesity and impaired glucose tolerance caused by HFD, reduces the blood fat level, alleviates inflammation, protects the liver, alleviates liver fat vacuole deposition and fatty degeneration, and has a good application prospect. It is proved that the bile acid-hawthorn and pericarpium citri reticulatae-clostridium butyricum combination has prevention and treatment and protection effects on the HFD-induced non-alcoholic fatty liver disease.

The present invention provides a method and system for evaluating various liver pathologies based on machine learning, which obtains the weight information, clinical examination information, and evaluation results of liver tissue samples of multiple historical patients; based on the obtained information, performs data preprocessing to construct a training set and a test set; uses the training set to train Logistic regression and Ridge regression models to determine the performance of the models in predicting ballooning degeneration, steatosis, lobular inflammation, significant fibrosis, and NASH, and determines the final prediction index parameters and prediction models; obtains the weight information, clinical examination information, and evaluation results of liver tissue samples of a patient, extracts the numerical values related to the prediction index parameters therefrom, and processes them with the determined trained prediction models for the corresponding prediction index parameters to obtain the final prediction results. The present invention constructs a simple model by obtaining clinical indicators and can comprehensively evaluate all aspects of the liver pathology of chronic liver diseases.

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

The invention relates to the technical field of biological medicines, and discloses an application of N2L in preparation of medicines for preventing and treating obesity and fatty liver, and the N2L is a dimer compound of alpha-lipoic acid and nicotinic acid. According to the embodiment of the invention, the application value of the GPR109A and GLP-1R double-target collaborative strategy in obesity and fatty liver treatment is proposed and verified for the first time, and the small molecule compound N2L with the GPR109A and GLP-1R double-target collaborative strategy can improve muscle endurance while reducing the weight of obese patients and can improve liver fatty degeneration at the same time. The defect that an existing GLP-1R agonist needs to be injected is overcome, meanwhile, the flushing side effect of an existing GPR109A agonist nicotinic acid medicine is avoided, a larger range is provided for medicine selection in the fields of obesity and fatty liver, and meanwhile, the application range of N2L is widened.

The present application relates to the microRNA drug technical field, specifically to the application of hsa-let-7f-5p in the preparation of a drug for treating muscle steatosis, and discloses that hsa-let-7f-5p can inhibit muscle fat infiltration by inhibiting fibroblast / adipogenic progenitor cell adipogenic differentiation, and hsa-let-7f-5p can be used as a microRNA drug in the treatment of diseases such as muscle fat infiltration and muscle steatosis, and diseases related to fat infiltration, for example, muscle atrophy, muscle injury, obesity, diabetes, etc. The relevant nucleic acid fragments are wrapped in liposomes, so that the drug stability and drug efficiency can be improved. The technical scheme can solve the technical problem that there is no drug capable of effectively inhibiting muscle steatosis and treating muscle injury in the prior art, and has an ideal application and promotion prospect in the fields of sports medicine and rehabilitation treatment.

The Applicant has discovered that the peptide of SEQUENCE ID NO: 1 (WKDEAGKPLVK) mediates changes in key biomarker activities associated with NASH (Table 1), and that the peptide is capable of penetrating HepG2 liver cells in a hepatic cell penetration assay (FIG. 1). In addition, the Applicant demonstrates that treatment with pep_260 (SEQ ID 1) for 44 days significantly relieves macro-vesicular steatosis in obese diabetic KKAy mice (FIG. 2) In a first aspect, the invention relates to the use of a peptide comprising SEQUENCE ID NO: 1, or a functional (or therapeutically effective) variant or functional fragment of SEQUENCE ID NO: 1 (hereafter “peptide active agent” or “peptide of the invention”), in a method for the treatment or prevention of non-alcoholic fatty liver disease (NAFLD), in particular non-alcoholic steatohepatitis (NASH), in a mammal.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD), is a condition characterized by the accumulation of fat in the liver of individuals with no alcohol consumption, and at least one cardiometabolic risk factor (overweight / obesity, high blood pressure, high blood sugar, high triglycerides levels, low HDL-C levels). The inventors demonstrated that Rab30 silencing improve metabolic dysfunction–associated steatotic liver disease (MASLD). The present invention relates to a method for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) in a subject in need thereof comprising the administration of a therapeutically effective amount of an inhibitor of Rab30.

(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis.

The invention discloses application of knockout or inhibition of intestinal epithelium Ufbp1 gene expression in preparation of medicines for preventing and / or treating obesity, and belongs to the technical field of biological medicines. In order to solve the problems of limited effect, many side effects and the like of the existing obesity treatment means, the invention provides Ufbp1 specifically expressed by intestinal epithelial cells as a new anti-obesity intervention target for the first time. By knocking out or inhibiting intestinal epithelium Ufbp1, weight gain, adipose tissue accumulation, hyperlipidemia, liver fatty degeneration and insulin resistance induced by high fat diet can be effectively resisted. The action mechanism is related to influence on secretion of intestinal apolipoprotein ApoB48 / ApoA1 and further regulation and control of whole body lipid metabolism. The invention provides a clear target and theoretical basis for developing novel anti-obesity therapies such as small-molecule inhibitors and nucleic acid drugs of targeted intestinal epithelium Ufbp1, and has important clinical transformation prospects.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,whereinwherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compoundsfor the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).